Avita Medical Inc. (RCEL) — Stock Valuation & Research

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use…

RCEL key statistics

Price$16.16
Market cap$401.51M
SectorHealthcare
IndustryMedical - Devices
ExchangeNASDAQ
52-week range3.22-16.9
Beta1.99

Explore RCEL's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.